No­var­tis to seek ap­provals in two rare kid­ney dis­eases af­ter pos­i­tive Phase 3 tri­als

No­var­tis is build­ing out its rare kid­ney dis­ease port­fo­lio with two batch­es of Phase 3 da­ta at the Eu­ro­pean Re­nal As­so­ci­a­tion con­fer­ence, tout­ing pos­i­tive re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.